John V. Soden
Cain Brothers Experience
John Soden is a Managing Director focused on Medical Technologies, including life science tools/reagents, diagnostics and labs, and medical devices and related services. He is also the Head of Mergers & Acquisitions at Cain Brothers. John joined the firm in early 2016. He has over 25 years of investment banking experience, primarily focused on private and public company M&A. His recent advisory transactions include the sale of Generate Life Sciences to CooperCompanies ($1.6bn), Generate Life Sciences’ acquisition of Cell Care Group, Arlington Capital Partners’ acquisition of Millstone Medical Outsourcing, the sale of Northfield Medical to Agiliti ($475mm), Linden Capital Partners and Audax Private Equity’s acquisition of StatLab Medical Products, the sale of Advanced Instruments to Patricia Industries, Blackstone’s investment in Sema4, the sale of SeraCare Life Sciences to LGC, California Cryobank’s sale to GI Partners and its simultaneous merger with Cord Blood Registry, and Patricia Industries’ acquisition of Sarnova from Water Street ($903mm). His recent capital raising transactions include public equity offerings for Agiliti, Codex DNA, LeMaitre Vascular, Maravai LifeSciences, Recursion, Sotera Health, and Stevanato Group.
Previously, John was a Managing Director & Head of Medical Technologies at Houlihan Lokey for approximately seven years. His transactions immediately prior to joining Cain Brothers included the sale of Hygiena to Warburg Pincus, Galil Medical to BTG Plc, CORPAK MedSystems (owned by Linden) to Halyard Health, Cord Blood Registry (owned by GTCR) to AMAG Pharmaceuticals, Ivera Medical to 3M, Integrated Medical Systems (IMS) to Steris, and Angiotech’s Interventional business to Argon Medical Devices (then owned by RoundTable). Notable restructuring experience included creditor representations with respect to Ameritox and Angiotech Pharmaceuticals. Before Houlihan Lokey, he worked for over six years in the Healthcare Group at Thomas Weisel Partners, most recently as a Managing Director, and prior to that, at UBS as a Director in both the M&A and Healthcare groups (originally joining a predecessor firm called Dillon, Read & Co.). He began his investment banking career as a Financial Analyst at CS First Boston in 1994.
John earned a BA in Economics (with Honors) from Northwestern University.